A data-rich thought piece by New Cannabis Ventures makes an interesting case for using a sum-of-the-parts analysis in valuing cannabis companies with diverse operating segments, as that helps filter out any boosted value that might be otherwise be included by a simple EBITDA analysis that inflates the overall valuation by including non-cannabis operating segments. The
LAVA: M&A Trends in the Cannabis Industry
Los Angeles Venture Association (LAVA) recently hosted a webinar discussing the recent uptick of merger and acquisition activity over the last six months, and the trends that will impact the future of the market.
Two reasons for the uptick in cannabis industry investments are confidence in the economy and elections which helped legalize cannabis. Momentum
Del. Appraisal Case Awards 2.6% Premium to Merger Price
This newest piece from Law.com [$$] analyzes the most recent appraisal decision from the Delaware Chancery Court, Regal Entertainment Group, in which the court awarded stockholders a 2.6% premium to merger price. The valuation determination followed from the court’s pegging Regal’s fair value to merger price less synergies, while adding back the increase in
Cannabis Valuation: Some Stops On the Road to Legalization
Global X, an ETF provider, provided this thorough but succinct survey highlighting the progress toward cannabis legalization in U.S. states.; this is part 1 of a 3-part series, so more to come. As we’ve noted before, cannabis valuation issues are intertwined with regulatory and legalization issues, an interesting, but not necessarily unique
Revisiting Deference to So-Called “Market Price” In Appraisal Litigation
This recent piece from Forbes provides an interesting look into how Michael Dell scored a huge windfall by opportunistically taking Dell private while the stock was undervalued. Although the Delaware trial court had acknowledged a valuation much higher than the take-private price, the Supreme Court reversed mainly on policy grounds, on the rationale that public
CannaLaw: Final Day & What’s Next?
Cannalaw Conference Wrap-up: What’s Next for Marijuana?
The conference closed with a look ahead to the future of the cannabis industry, patent issues, and emerging psychedelic market. What will we see with regards to patent enforcement? Only two cannabis related lawsuits have been filed to date, one that died. However, there is speculation that
CannaLaw: Valuation of Cannabis Targets
The M&A panel at yesterday’s Cannalaw conference addressed what valuation techniques are being used to determine the purchase price of a marijuana company. While in recent years the traditional valuation metrics would normally be utilized – whether multiples of sales, revenues or EBITDA, for instance – the current market is experiencing a supply/demand imbalance, as
CannaLaw Day 2: Additional Panels on Issues in Cannabis Law
Financial Inclusion: Banking in the Legal Cannabis Industry
The panel focused on the challenges of cannabis banking, including availability, compliance issues and whether the proposed Safe Banking Act will pass. The major problem that large banks face is not with the illegality of cannabis, but with the compliance costs. Large banks must file a
CannaLaw Summit: Day 1
RKS is covering the the Cannalaw Summit, a conference covering a range of topics including cannabis valuation. Beyond the newest US states to legalize recreational cannabis use, Mexico is proceeding with legalization steps in what observers said could become “the world’s largest cannabis market.” The summit kicked off yesterday covering an industry “with projections of
Cannabis Valuation Space Becoming “Smoking Hot”
In this new post, major asset manager Alger spotlights the growing cannabis sector and underscores investors’ opportunities alongside increased public support and favorable legislative changes.
For more on factors affecting cannabis business valuation, including regulatory changes and legalization pushes, see our topic area.